BEAMER

World Evidence, Pricing and Access Congress Day 1, done ✅! We are happy to be present in Amsterdam to talk about ways to enhance patient adherence, clinical studies, and the BEAMER project in general. You can meet BEAMER members Claire Everitt, Adriaan Rudolf Liefveld and Simon Klaasen at booth number 92 🤝 Later today, Claire will give a presentation on "How the B-COMPASS is improving patient support, outcomes and cost-effectiveness”, in the Health Economics and Outcomes Research track of the conference. 😊

💥 BEAMER members are ready for the World Evidence, Pricing and Access Congress in Amsterdam! 🔹 Claire Everitt will give a presentation on how the B-COMPASS is improving patient support, outcomes, and cost-effectiveness 🔹 Simon Klaasen and Adriaan Rudolf Liefveld will be at booth number 92 to talk about ways to enhance patient adherence, clinical studies, and the BEAMER project in general. Come say hi!👋 We are thrilled to meet and connect with stakeholders from the pharma, biotech, and Payers/HTA sectors 🤝

🗯️ 🖇️ What are the effects of non-adherence to treatment in clinical trials? In this second article, Adriaan Rudolf Liefveld explains how avoidable non-adherent behavior also exists in clinical trials, and what are the consequences. Access it now! 🤗 👇 https://lnkd.in/dqZQ-M3h

🕰️ One week to go... ...until BEAMER partners Claire Everitt and Adriaan Rudolf Liefveld will participate to the World EPA Congress 2025, in Amsterdam. On 6 March, Claire Everitt will give a presentation on 'How the B-COMPASS is improving patient support, outcomes, and cost-effectiveness', while Adriaan Rudolf Liefveld will hold a booth (nr 92) at the congress exhibition. It will be an amazing occasion to meet and connect with stakeholders from the pharma, biotech, and Payers/HTA sectors. 🤗 More info 👇 #EPA #beamerproject #patientadherence https://lnkd.in/ehqkxfi8

🤔 🗯️ What are the factors that influence adherence to treatment? How does it affect health outcomes? 🖇️ In this publication, BEAMER members Adriaan Rudolf Liefveld and Claire Everitt write about how adherence to treatment is a critical, yet often overlooked factor in patient outcomes. They explore possible solutions by understanding why patients struggle with adherence (beyond just demographics), but through behavioral science. Access the full article here 👇 #Healthcare #Adherence #PatientCare #BEAMER #MedicalResearch #BehavioralScience https://lnkd.in/dqZQ-M3h

🕰️ In two weeks BEAMER partners Claire Everitt and Adriaan Rudolf Liefveld will participate to the World EPA Congress 2025. 📅 5-6 March 2025 📍 Amsterdam On 6 March, Claire Everitt will hold a presentation on 'How the B-COMPASS is improving patient support, outcomes, and cost-effectiveness', while Adriaan Rudolf Liefveld will hold a booth (nr 92) at the congress exhibition. It will be an amazing occasion to meet and connect with stakeholders from the pharma, biotech, and Payers/HTA sectors. 🤗 More info 👇 #EPA #beamerproject #patientadherence https://lnkd.in/ehqkxfi8

Last 6 February, BEAMER members Kristina Livitckaia and Konstantina Pantelidou participated in the DATAMITE Meetup event. Kristina was involved in a panel on Data Exploitation in the Health Sector while Konstantina disseminated technical results of WP1 and WP3 and emphasised the core place of the B-COMPASS framework. BEAMER representation to events like these is crucial to exchange knowledge on data-driven innovation with researchers and industry professionals. We are thrilled to share the replay of the panel now! 🙌 👇 Centre for Research & Technology Hellas (CERTH) OTE Group of Companies (HTO) #HorizonEU #DATAMITEMeetUp https://lnkd.in/dBP-W64a

🎁 Happy Holidays from the #BEAMER project 🎁 Together with our partners, we are dedicated, through the developed BEAMER framework (B-COMPASS), to helping build solutions that enable healthcare stakeholders to provide personalised patient support and improve adherence behaviour 💡 🙌 Thank you for being part of the #BEAMER project! As we are entering the exciting time when more results emerge, we invite #PatientOrganisations #HealthcareManagers #Regulators and all other interested groups to follow our journey 👋 Innovative Health Initiative (IHI) Universidad Politécnica de Madrid Centre for Research & Technology Hellas (CERTH) University of Oslo Servicio madrileño de salud (SERMAS) empirica Communication and Technology Research Tilburg University APDP Diabetes ECHAlliance - The Global Health Connector Akershus universitetssykehus World Duchenne Organization Innovation Sprint MYSPHERA IDIAPJGol PredictBy Link2Trials EFPIA - European Federation of Pharmaceutical Industries and Associations

📑 The ESPACOMP International Society for Medication Adherence is an interprofessional association dedicated to promoting cutting-edge research in the field of medication adherence. Last 22 November, representatives of the BEAMER team presented the new B-COMPASS model to the adherence community at the ESPACOMP Annual Conference in Naples. The model helps to understand the needs of different patient groups, enabling users to tailor more effective support. Further studies to validate the model are planned for 2025. 🧐 Claire Everitt

Yes!!! This week we have received the details about our booth at the 2025 World EPA Congress in Amsterdam!! On March 5-6, 2025 Link2Trials and the BEAMER project will be at the World Evidence, Pricing and Access Congress in Amsterdam. BEAMER Industry Project Lead Claire Everitt of Pfizer will speak on March 6 about how the B-COMPASS framework addresses all the HEOR top 10 focus areas, from Health Equity and Patient-Centricity to Value and Pricing, providing a foundation for future development in precision medicine. You can meet Claire Everitt, Simon Klaasen, and Adriaan Rudolf Liefveld at booth 92, and learn about the many benefits BEAMER will provide patients, HCP's, pharma companies, regulators, payers, and policy makers! https://lnkd.in/dTusjZX #beamerproject #patientadherence #patientengagement #clinicalresearch #clinicalcare #clinicaloperations #healthcareinnovations #patientoutcomes #healtheconomics #healthcareprofessionals #healthinsurancepolicy #regulators